MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/liv.14858

Медицинская библиотека · Liver international : official journal of the International Association for the Study of the Liver · 2021

Real-world effectiveness and safety of direct-acting antivirals in patients with cirrhosis and history of hepatic decompensation: Epi-Ter2 Study.

Berkan-Kawińska Aleksandra, Piekarska Anna, Janczewska Ewa, Lorenc Beata, Tudrujek-Zdunek Magdalena, Tomasiewicz Krzysztof, Berak Hanna, Horban Andrzej, Zarębska-Michaluk Dorota, Pabjan Paweł, Buczyńska Iwona, Pazgan-Simon Monika, Dybowska Dorota, Halota Waldemar, Pawłowska Małgorzata, Klapaczyński Jakub, Mazur Włodzimierz, Czauż-Andrzejuk Agnieszka, Socha Łukasz, Laurans Łukasz, Garlicki Aleksander, Sitko Marek, Jaroszewicz Jerzy, Citko Jolanta, Dobracka Beata, Krygier Rafał, Białkowska-Warzecha Jolanta, Tronina Olga, Belica-Wdowik Teresa, Baka-Ćwierz Barbara, Flisiak Robert

СтатьяПеревод в очереди

Аннотация

BACKGROUND AND AIMS: The aim of this study was to assess the real-life effectiveness and safety of direct acting antivirals (DAAs) in patients with cirrhosis and history of hepatic decompensation compared to those with compensated cirrhosis.

METHOD: Data of patients treated with DAAs and included in the EpiTer-2 database (N = 10 152) were collected retrospectively. The primary endpoint was sustained viral response (SVR) at 12 weeks posttreatment. Patients were also evaluated in terms of liver-related adverse events and treatment modification/discontinuation.

RESULTS

The overall SVR rate was 91.4% in the intent to treat (ITT) analysis and 95.2% in the per-protocol (PP) analysis (P < .001). Patients with decompensated cirrhosis had lower SVR rates compared to those with compensated cirrhosis in ITT analysis (86.4% vs 92.0%, P < .001), while not in PP analysis (92.9% vs 95.5%, P > .05). Adverse events (AE) occurred 45.6% and 29.3% of patients with decompensated and compensated cirrhosis (P < .001). Patients with decompensated cirrhosis were at higher risk of death (5.4% vs 0.9%; P < .0001) or liver decompensation (21.5% vs 1.3%; P < .0001). Treatment with protease inhibitors was not associated with hepatic decompensation (P = .3). Only 82.6% of patients with decompensated cirrhosis completed DAA treatment (vs 92.8% in compensated cirrhotics; P < .0001).

CONCLUSION

Despite higher frequency of AE and treatment modifications, once completed, DAAs yield comparable results for patients with decompensated and compensated cirrhosis. High rate of serious adverse events in patients with advanced liver disease treated with PI may not be related to the detrimental effect of the medications, but rather to the disease itself.

Для цитирования: Berkan-Kawińska Aleksandra, Piekarska Anna, Janczewska Ewa, Lorenc Beata, Tudrujek-Zdunek Magdalena, Tomasiewicz Krzysztof, Berak Hanna, Horban Andrzej, Zarębska-Michaluk Dorota, Pabjan Paweł, Buczyńska Iwona, Pazgan-Simon Monika, Dybowska Dorota, Halota Waldemar, Pawłowska Małgorzata, Klapaczyński Jakub, Mazur Włodzimierz, Czauż-Andrzejuk Agnieszka, Socha Łukasz, Laurans Łukasz, Garlicki Aleksander, Sitko Marek, Jaroszewicz Jerzy, Citko Jolanta, Dobracka Beata, Krygier Rafał, Białkowska-Warzecha Jolanta, Tronina Olga, Belica-Wdowik Teresa, Baka-Ćwierz Barbara, Flisiak Robert. Real-world effectiveness and safety of direct-acting antivirals in patients with cirrhosis and history of hepatic decompensation: Epi-Ter2 Study.. Liver international : official journal of the International Association for the Study of the Liver. 2021. DOI: 10.1111/liv.14858.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.